Table 1.
Current studies of SARS-CoV-2 positive athletes who underwent CMR evaluation for return-to-play.
| STUDIES | Cohort/Characteristics | Days to CMR | Abnormal CMR | ↑T1 | ↑T2 | LGE | LV Function | RV Function | Pericardial Effusion | Diagnosis of Myocarditis | Resolution of Myocarditis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brito(33) |
54 college athletes 46 (85.2%) men 37 (70%) symptomatic 48 underwent CMR |
27 |
27 (56.3%) | 9 (18.75%) | 0 | 1 (2%) | 59.91% | 53.58% | 28 (58.3%) | Not Reported | Not Studied |
| Clark(31) |
59 college athletes 37 (63%) women 46 (78%) symptomatic 59 underwent CMR |
21.5 | Not Reported | Not Reported | Not Reported | 27 (16%) | 60% | 53% | 1 (2%) | 2 (3%) | Not Studied |
| Daniels(34) |
2461 college athletes 1879 (66.9%) men Symptoms not reported 1597 underwent CMR |
22 | Not Reported | 5 (0.3%) | 31 (1.9%) | 37 (2.3%) | Not Reported | Not Reported | Not Reported | 37 (2.3%) | 100% T2 resolved 43% residual LGE 40.7% resolved LGE 27% pending imaging |
| Martinez(35) |
789 professional athletes 777 (98.5%) men 460 (58.3%) symptomatic 27 underwent CMR |
17 | Not Reported | Not Reported | Not Reported | 3 (11%) | Not Reported | Not Reported | Not Reported | 5 (0.6%) | Not Studied |
| Moulson(36) |
3018 college athletes 965 (32%) women 2022 (67%) symptomatic 317 underwent CMR |
33 | Not Reported | 7 (2%) | 7 (2%) | 12 (4%) | Not Reported | Not Reported | 13 (4%) | 15 (0.7%) | Not Studied |
| Rajpal(22) |
26 college athletes 15 (57.7%) men 12 (26.9%) symptomatic 26 underwent CMR |
11-53 | 46% | 9 (45%) | 13 (50%) | 12 (46%) | 58% | 57% | 2 (8%) | 4 (15%) | Not Studied |
| Mitrani(37) |
174 professional athletes 122 (70%) men 148 (85.1%) symptomatic 28 underwent CMR |
21 | 5 | 2 | 1 | 3 | 56.8% | 43% (3/5 reported) | 3 | (2) 1.1% | 100% |
CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricle; RV, right ventricle; LVEDV, left ventricular end-diastolic volume